Safety and efficacy of continuous intravenous labetalol for blood pressure control in neurosurgical patients.

"The authors declare that there is no conflict of interest."

"Funding: This study was funded by the Great Eastern Drug Company, Thailand, which also provided financial support for the journal’s publication fee. The company was not involved in any other aspect of the study, including the study design, data collection, data analysis, or presentation of results."

"This study was a retrospective review that investigated the efficacy and safety of continuous intravenous infusion of labetalol for BP control in neurosurgical patients who were admitted to our institution between 1 November 2021 and 31 October 2022. This study was conducted in accordance with the Declaration of Helsinki and was approved by the Human Research Ethics Committee of Thammasat University (Medicine) (Approval No. 245/2022); for this type of retrospective study, formal consent is not required. The study was registered with the Thai Clinical Trials Registry (TCTR20221227005). All patients’ details were de-identified. The reporting of this study conforms to the STROBE guidelines."